Dyskinesias and impulse control disorders in Parkinson's disease: From pathogenesis to potential therapeutic approaches

Neuroscience and Biobehavioral Reviews

Volumn 56, Issue , 2015, Pages 294-314

  Jiménez Urbieta, Haritz ^a,b   Gago, Belén ^a,b   de la Riva, Patricia ^c   Delgado Alvarado, Manuel ^a,b   Marin, Concepció ^d   Rodriguez Oroz, María C ^a,b,c,e  

^a BIODONOSTIA HEALTH RESEARCH INSTITUTE   (Spain)

^b CENTRO DE INVESTIGACIÓN BIOMÉDICA EN RED SOBRE ENFERMEDADES NEURODEGENERATIVAS CIBERNED   (Spain)

^c HOSPITAL DONOSTIA   (Spain)

^d INSTITUT D INVESTIGACIONS BIOMÈDIQUES AUGUST PI I SUNYER IDIBAPS   (Spain)

^e BASQUE FOUNDATION FOR SCIENCE   (Spain)

Author keywords

Basal ganglia; Behavioral addiction; Dopaminergic drugs; Genetics; Impulse control disorders; Levodopa induced dyskinesias; Neurochemistry; Neuroimaging; Parkinson's disease; Pathophysiology; Pharmacology; Risk factors

Indexed keywords

LEVODOPA; DOPAMINE;

ADRENERGIC TRANSMISSION; BIOCHEMISTRY; DEMOGRAPHY; DISEASE ASSOCIATION; DISEASE PREDISPOSITION; DOPAMINERGIC SYSTEM; DRUG DEPENDENCE; DRUG SAFETY; DYSKINESIA; GABAERGIC SYSTEM; GLUTAMATERGIC SYNAPSE; HEREDITY; HUMAN; IMPULSE CONTROL DISORDER; MOTOR DYSFUNCTION; NONHUMAN; PARKINSON DISEASE; PATHOGENESIS; PRIORITY JOURNAL; REVIEW; RISK FACTOR; TREATMENT PLANNING; ANIMAL; COMPLICATION; DISRUPTIVE, IMPULSE CONTROL, AND CONDUCT DISORDERS; DYSKINESIAS; METABOLISM; PATHOLOGY;

ANIMALS; DISRUPTIVE, IMPULSE CONTROL, AND CONDUCT DISORDERS; DOPAMINE; DYSKINESIAS; HUMANS; PARKINSON DISEASE;

EID: 84938890302     PISSN: 01497634     EISSN: 18737528     Source Type: Journal    
DOI: 10.1016/j.neubiorev.2015.07.010     Document Type: Review

References (380)

1. Achat-Mendes C., Platt D.M., Spealman R.D. Antagonism of metabotropic glutamate 1 receptors attenuates behavioral effects of cocaine and methamphetamine in squirrel monkeys. J. Pharmacol. Exp. Ther. 2012, 343(1):214-224.
2. Adi Y., Juarez-Garcia A., Wang D., Jowett S., Frew E., Day E., Bayliss S., Roberts T., Burls A. Oral naltrexone as a treatment for relapse prevention in formerly opioid-dependent drug users: a systematic review and economic evaluation. Health Technol. Assess. 2007, 11(6):iii-iv. 1-85.
3. Adler C.H., Sethi K.D., Hauser R.A., Davis T.L., Hammerstad J.P., Bertoni J., Taylor R.L., Sanchez-Ramos J., O'Brien C.F. Ropinirole for the treatment of early Parkinson's disease. The Ropinirole Study Group. Neurology 1997, 49(2):393-399.
4. Alachkar A., Brotchie J.M., Jones O.T. Changes in the mRNA levels of α2A and α2C adrenergic receptors in rat models of Parkinson's disease and levodopa-induced dyskinesia. J. Mol. Neurosci. 2012, 46(1):145-152.
5. Al Ameri M., Al Mansouri S., Al Maamari A., Bahi A. The histone deacetylase (HDAC) inhibitor valproic acid reduces ethanol consumption and ethanol-conditioned place preference in rats. Brain Res. 2014, 1583:122-131.
6. Alexander G.E., DeLong M.R., Strick P.L. Parallel organization of functionally segregated circuits linking basal ganglia and cortex. Annu. Rev. Neurosci. 1986, 9:357-381.
7. Diagnostic and Statistical Manual of Mental Disorders 1994, American Psychiatric Association, American Psychiatric Association, Washington, D.C. 4th ed.
8. Diagnostic and Statistical Manual of Mental Disorders 2013, American Psychiatric Association, American Psychiatric Association, Washington, D.C. 5th ed.
9. Amalric M., Koob G.F. Functionally selective neurochemical afferents and efferents of the mesocorticolimbic and nigrostriatal dopamine system. Prog. Brain Res. 1993, 99:209-226.
10. Amitai N., Semenova S., Markou A. Cognitive-disruptive effects of the psychotomimetic phencyclidine and attenuation by atypical antipsychotic medications in rats. Psychopharmacology (Berl.) 2007, 193(4):521-537.
11. Amitai N., Markou A. Increased impulsivity and disrupted attention induced by repeated phencyclidine are not attenuated by chronic quetiapine treatment. Pharmacol. Biochem. Behav. 2009, 93(3):248-257.
12. Aron A.R., Robbins T.W., Poldrack R.A. Inhibition and the right inferior frontal cortex. Trends Cogn. Sci. 2004, 18(4):177-185.
13. Aron A.R. From reactive to proactive and selective control: developing a richer model for stopping inappropriate responses. Biol. Psychiatry 2011, 69(12):e55-e68.
14. Aubert I., Guigoni C., Håkansson K., Li Q., Dovero S., Barthe N., Bioulac B.H., Gross C.E., Fisone G., Bloch B., Bezard E. Increased D1 dopamine receptor signaling in levodopa-induced dyskinesia. Ann. Neurol. 2005, 57(1):17-26.
15. Aubert I., Guigoni C., Li Q., Dovero S., Bioulac B.H., Gross C.E., Crossman A.R., Bloch B., Bezard E. Enhanced preproenkephalin-B-derived opioid transmission in striatum and subthalamic nucleus converges upon globus pallidus internalis in L-3,4-dihydroxyphenylalanine-induced dyskinesia. Biol. Psychiatry 2007, 61(7):836-844.
16. Baler R.D., Volkow N.D. Drug addiction: the neurobiology of disrupted self-control. Trends Mol. Med. 2006, 12:559-566.
17. Ballivet J., Marin A., Gisselmann A. Aspects of hypersexuality observed in parkinsonian patients treated by Levodopa. Ann. Med. Psychol. (Paris) 1973, 2(4):515-522.
18. Bandelow B., Sher L., Bunevicius R., Hollander E., Kasper S., Zohar J., Möller H.J. WFSBP Task Force on Mental Disorders in Primary Care; WFSBP Task Force on Anxiety Disorders, OCD and PTSD. Guidelines for the pharmacological treatment of anxiety disorders, obsessive-compulsive disorder and posttraumatic stress disorder in primary care. Int. J. Psychiatry Clin. Pract. 2012, 16(2):77-84.
19. Bara-Jimenez W., Sherzai A., Dimitrova T., Favit A., Bibbiani F., Gillespie M., Morris M.J., Mouradian M.M., Chase T.N. Adenosine A2A receptor antagonist treatment of Parkinson's disease. Neurology 2003, 61:293-296.
20. Bara-Jimenez W., Bibbiani F., Morris M.J., Dimitrova T., Sherzai A., Mouradian M.M., Chase T.N. Effects of serotonin 5-HT1A agonist in advanced Parkinson's disease. Mov. Disord. 2005, 20(8):932-936.
21. Baron M.S., Dalton W.B. Quetiapine as treatment for dopaminergic-induced dyskinesias in Parkinson's disease. Mov. Disord. 2003, 18(10):1208-1209.
22. Bastiaens J., Dorfman B.J., Christos P.J., Nirenberg M.J. Prospective cohort study of impulse control disorders in Parkinson's disease. Mov. Disord. 2013, 28(3):327-333.
23. Beninger R.J. The role of dopamine in locomotor activity and learning. Brain Res. 1983, 287:173-196.
24. Berg D., Godau J., Trenkwalder C., Eggert K., Csoti I., Storch A., Huber H., Morelli-Canelo M., Stamelou M., Ries V., Wolz M., Schneider C., Di Paolo T., Gasparini F., Hariry S., Vandemeulebroecke M., Abi-Saab W., Cooke K., Johns D., Gomez-Mancilla B. AFQ056 treatment of levodopa-induced dyskinesias: results of 2 randomized controlled trials. Mov. Disord. 2011, 26(7):1243-1250.
25. Bermejo P.E. Topiramate in managing impulse control disorders in Parkinson's disease. Parkinsonism Relat. Disord. 2008, 14(5):448-449.
26. Bermejo P.E., Ruiz-Huete C., Anciones B. Zonisamide in managing impulse control disorders in Parkinson's disease. J. Neurol. 2010, 257(10):1682-1685.
27. Berthet A., Porras G., Doudnikoff E., Stark H., Cador M., Bezard E., Bloch B. Pharmacological analysis demonstrates dramatic alteration of D1 dopamine receptor neuronal distribution in the rat analog of levodopa-induced dyskinesia. J. Neurosci. 2009, 29(15):4829-4835.
28. Besheer J., Faccidomo S., Grondin J.J., Hodge C.W. Effects of mGlu1-receptor blockade on ethanol self-administration in inbred alcohol-preferring rats. Alcohol 2008, 42(1):13-20.
29. Bettler B., Kaupmann K., Mosbacher J., Gassman M. Molecular structure and physiological functions of GABA(B) receptors. Physiol. Rev. 2004, 84:835-867.
30. Bezard E., Ferry S., Mach U., Stark H., Leriche L., Boraud T., Gross C., Sokoloff P. Attenuation of levodopa-induced dyskinesia by normalizing dopamine D3 receptor function. Nat. Med. 2003, 9:762-767.
31. Bezard E., Gross C.E., Qin L., Gurevich V.V., Benovic J.L., Gurevich E.V. Levodopa reverses the MPTP-induced elevation of the arrestin2 and GRK6 expression and enhanced ERK activation in monkey brain. Neurobiol. Dis. 2005, 18(2):323-335.
32. Bharmal A., Lu C., Quickfall J., Crockford D., Suchowersky O. Outcomes of patients with Parkinson disease and pathological gambling. Can. J. Neurol. Sci. 2010, 37(4):473-477.
33. Bibbiani F., Oh J.D., Petzer J.P., Castagnoli N., Chen J.F., Schwarzschild M.A., Chase T.N. A2A antagonist prevents dopamine agonist-induced motor complications in animal models of Parkinson's disease. Exp. Neurol. 2003, 184(1):285-294.
34. Bishop C., Taylor J.L., Kuhn D.M., Eskow K.L., Park J.Y., Walker P.D. MDMA and fenfluramine reduce l-DOPA-induced dyskinesia via indirect 5-HT1A receptor stimulation. Eur. J. Neurosci. 2006, 23(10):2669-2676.
35. Bishop C., George J.A., Buchta W., Goldenberg A.A., Mohamed M., Dickinson S.O., Eissa S., Eskow Jaunarajs K.L. Serotonin transporter inhibition attenuates levodopa-induced dyskinesia without compromising levodopa efficacy in hemi-parkinsonian rats. Eur. J. Neurosci. 2012, 36(6):2839-2848.
36. Blanchet P.J., Papa S.M., Metman L.V., Mouradian M.M., Chase T.N. Modulation of levodopa-induced motor response complications by NMDA antagonists in Parkinson's disease. Neurosci. Biobehav. Rev. 1997, 21(4):447-453.
37. Bonifati V., Fabrizio E., Cipriani R., Vanacore N., Meco G. Buspirone in levodopa-induced dyskinesias. Clin. Neuropharmacol. 1994, 17(1):73-82.
38. Bordet R., Ridray S., Schwartz J.C., Sokoloff P. Induction of dopamine D3 receptor expression as a mechanism of behavioral sensitization in 6-hydroxidopamine-lesioned rats. Eur. J. Neurosci. 2000, 12(6):2117-2123.
39. Bosco D., Plastino M., Colica C., Bosco F., Arianna S., Vecchio A., Galati F., Cristiano D., Consoli A., Consoli D. Opioid antagonist naltrexone for the treatment of pathological gambling in Parkinson disease. Clin. Neuropharmacol. 2012, 35(3):118-120.
40. Bostwick J.M., Bucci J.A. Internet sex addiction treated with naltrexone. Mayo Clin. Proc. 2008, 83(2):226-230.
41. Braz C.A., Borges V., Ferraz H.B. Effect of riluzole on dyskinesia and duration of the on state in Parkinson disease patients: a double-blind, placebo-controlled pilot study. Clin. Neuropharmacol. 2004, 27(1):25-29.
42. Breiter H.C., Gollub R.L., Weisskoff R.M., Kennedy D.N., Makris N., Berke J.D., Goodman J.M., Kantor H.L., Gastfriend D.R., Riorden J.P., Mathew R.T., Rosen B.R., Hyman S.E. Acute effects of cocaine on human brain activity and emotion. Neuron 1997, 19(3):591-611.
43. Breiter H.C., Aharon I., Kahneman D., Dale A., Shizgal P. Functional imaging of neural responses to expectancy and experience of monetary gains and losses. Neuron 2001, 30(2):619-639.
44. Brooks D.J., Piccini P., Turjanski N., Samuel M. Neuroimaging of dyskinesia. Ann. Neurol. 2000, 47(4 Suppl. 1):S154-S158.
45. Bruno F. Buspirone in the treatment of alcoholic patients. Psychopathology 1989, 22(Suppl. 1):49-59.
46. Buck K., Ferger B. The selective a1 adrenoceptor antagonist HEAT reduces levodopa-induced dyskinesia in a rat model of Parkinson's disease. Synapse 2010, 64:117-126.
47. Burmeister J.J., Lungren E.M., Neisewander J.L. Effects of fluoxetine and d-fenfluramine on cocaine-seeking behavior in rats. Psychopharmacology (Berl.) 2003, 168(1-2):146-154.
48. Calon F., Rajput A.H., Hornykiewicz O., Bédard P.J., Di Paolo T. Increase of preproenkephalin mRNA levels in the putamen of Parkinson disease patients with levodopa-induced dyskinesias. J. Neuropathol. Exp. Neurol. 2002, 61(2):186-196.
49. Calon F., Rajput A.H., Hornykiewicz O., Bédard P.J., Di Paolo T. Levodopa-induced motor complications are associated with alterations of glutamate receptors in Parkinson's disease. Neurobiol. Dis. 2003, 14(3):404-416.
50. Calon F., Dridi M., Hornykiewicz O., Bédard P.J., Rajput A.H., Di Paolo T. Increased adenosine A2A receptors in the brain of Parkinson's disease patients with dyskinesias. Brain 2004, 127(Pt 5):1075-1084.
51. Carlsson T., Carta M., Winkler C., Björklund A., Kirik D. Serotonin neuron transplants exacerbate l-DOPA-induced dyskinesias in a rat model of Parkinson's disease. J. Neurosci. 2007, 27(30):8011-8022.
52. Carpentier A.F., Bonnet A.M., Vidailhet M., Agid Y. Improvement of levodopa-induced dyskinesia by propranolol in Parkinson's disease. Neurology 1996, 46(6):1548-1551.
53. Carta M., Carlsson T., Kirik D., Björklund A. Dopamine released from 5-HT terminals is the cause of levodopa-induced dyskinesia in parkinsonian rats. Brain 2007, 130(7):1819-1833.
54. Cenci M.A., Lee C.S., Björklund A. l-DOPA-induced dyskinesia in the rat is associated with striatal overexpression of prodynorphin- and glutamic acid decarboxylase mRNA. Eur. J. Neurosci. 1998, 10(8):2694-2706.
55. Ceravolo R., Frosini D., Rossi C., Bonuccelli U. Spectrum of addictions in Parkinson's disease: from dopamine dysregulation syndrome to impulse control disorders. J. Neurol. 2010, 257(Suppl. 2):S276-S283.
56. Cerasa A., Pugliese P., Messina D., Morelli M., Gioia M.C., Salsone M., Novellino F., Nicoletti G., Arabia G., Quattrone A. Prefrontal alterations in Parkinson's disease with levodopa-induced dyskinesia during fMRI motor task. Mov. Disord. 2012, 27(3):364-371.
57. Chang L., Alicata D., Ernst T., Volkow N. Structural and metabolic brain changes in the striatum associated with methamphetamine abuse. Addiction 2007, 102(Suppl. 1):16-32.
58. Chase T.N., Oh J.D., Konitsiotis S. Antiparkinsonian and antidyskinetic activity of drugs targeting central glutamatergic mechanisms. J. Neurol. 2000, 247(Suppl. 2):II36-II42.
59. Chen L., Segal D.M., Moraes C.T., Mash D.C. Dopamine transporter mRNA in autopsy studies of chronic cocaine users. Brain Res. Mol. Brain Res. 1999, 73(1-2):181-185.
60. Childress A.R., Ehrman R.N., Wang Z., Li Y., Sciortino N., Hakun J., Jens W., Suh J., Listerud J., Marquez K., Franklin T., Langleben D., Detre J., O'Brien C.P. Prelude to passion: limbic activation by "unseen" drug and sexual cues. PLoS One 2008, 3(1):e1506.
61. Cilia R., Siri C., Marotta G., Isaias I.U., De Gaspari D., Canesi M., Pezzoli G., Antonini A. Functional abnormalities underlying pathological gambling in Parkinson disease. Arch. Neurol. 2008, 65(12):1604-1611.
62. Cilia R., Hyun Ko J., Sang Soo C., van Eimeren T., Marotta G., Pallecchia G., Pezzoli G., Antonini A., Strafella A.P. Reduced Dopamine Trasnporter density in the ventral striatum of patients with Parkinson's disease and pathological gambling. Neurobiol. Dis. 2010, 39(1):98-104.
63. Cilia R., Cho S.S., van Eimeren T., Marotta G., Siri C., Ko J.H., Pellecchia G., Pezzoli G., Antonini A., Strafella A.P. Pathological gambling in patients with Parkinson's disease is associated with fronto-striatal disconnection: a path modeling analysis. Mov. Disord. 2011, 26(2):225-233.
64. Cilia R., van Eimeren T. Impulse control disorders in Parkinson's disease: seeking a roadmap toward a better understanding. Brain Struct. Funct. 2011, 216(4):289-299.
65. Cilia R., Siri C., Canesi M., Zecchinelli A.L., De Gaspari D., Natuzzi F., Tesei S., Meucci N., Mariani C.B., Sacilotto G., Zini M., Ruffmann C., Pezzoli G. Dopamine dysregulation syndrome in Parkinson's disease: from clinical and neuropsychological characterisation to management and long-term outcome. J. Neurol. Neurosurg. Psychiatry 2014, 85(3):311-318.
66. Coccaro E.F., Kavoussi R.J. Fluoxetine and impulsive aggressive behavior in personality-disordered subjects. Arch. Gen. Psychiatry 1997, 54(12):1081-1088.
67. Cohen J., Dervaux A., Laqueille X. Topiramate in substance-related and addictive disorders. Presse Med. 2014, 43(9):892-901. (in French).
68. Collins G.T., Truong Y.N., Levant B., Chen J., Wang S., Woods J.H. Behavioral sensitization to cocaine in rats: evidence for temporal differences in dopamine D3 and D2 receptor sensitivity. Psychopharmacology (Berl.) 2011, 215(4):609-620.
69. Comings D.E., Blum K. Reward deficiency syndrome: genetic aspects of behavioral disorders. Prog. Brain Res. 2000, 126:325-341.
70. Connolly B.S., Lang A.E. Pharmacological treatment of Parkinson disease: a review. JAMA 2014, 311(16):1670-1683.
71. Conrad K.L., Ford K., Marinelli M., Wolf M.E. Dopamine receptor expression and distribution dynamically change in the rat nucleus accumbens after withdrawal from cocaine self-administration. Neuroscience 2010, 169(1):182-194.
72. Conti M.M., Ostock C.Y., Lindenbach D., Goldenberg A.A., Kampton E., Dell'isola R., Katzman A.C., Bishop C. Effects of prolonged selective serotonin reuptake inhibition on the development and expression of l-DOPA-induced dyskinesia in hemi-parkinsonian rats. Neuropharmacology 2014, 77:1-8.
73. Cosgrove K.P. Imaging receptor changes in human drug abusers. Curr. Top. Behav. Neurosci. 2010, 3:199-217.
74. Cunnington A.L., White L., Hood K. Identification of possible risk factors for the development of dopamine agonist withdrawal syndrome in Parkinson's disease. Parkinsonism Relat. Disord. 2012, 18(9):1051-1052.
75. Dagher A., Robbins T.W. Personality, addiction, dopamine: insights from Parkinson's disease. Neuron 2009, 61(4):502-510.
76. Daniele A., Albanese A., Gainotti G., Gregory B., Bartolomeo P. Zolpidem in Parkinson's disease. Lancet 1997, 349:679-681.
77. Dannon P.N. Topiramate for the treatment of kleptomania: a case series and review of the literature. Clin. Neuropharmacol. 2003, 26(1):1-4.
78. Dannon P.N., Lowengrub K., Gonopolski Y., Musin E., Kotler M. Topiramate versus fluvoxamine in the treatment of pathological gambling: a randomized, blind-rater comparison study. Clin. Neuropharmacol. 2005, 28:6-10.
79. Dekundy A., Pietraszek M., Schaefer D., Cenci M.A., Danysz W. Effects of group I metabotropic glutamate receptors blockade in experimental models of Parkinson's disease. Brain Res. Bull. 2006, 69(3):318-326.
80. Dekundy A., Lundblad M., Danysz W., Cenci M.A. Modulation of levodopa-induced abnormal involuntary movements by clinically tested compounds: further validation of the rat dyskinesia model. Behav. Brain Res. 2007, 179(1):76-89.
81. de Lau L.M., Verbaan D., Marinus J., Heutink P., van Hilten J.J. Catechol-O-methyltransferase Val158Met and the risk of dyskinesias in Parkinson's disease. Mov. Disord. 2012, 27(1):132-135.
82. De la Fuente-Fernández R., Sossi V., Huang Z., Furtado S., Jian-Qiang L., Calne D.B., Ruth T.J., Stoessl A.J. Levodopa-induced changes in synaptic dopamine levels increase with progression of Parkinson's disease: implications for dyskinesias. Brain 2004, 127(12):2747-2754.
83. Dell'Osso B., Altamura A.C., Mundo E., Marazziti D., Hollander E. Diagnosis and treatment of obsessive-compulsive disorder and related disorders. Int. J. Clin. Pract. 2007, 61(1):98-104.
84. Doucet J.P., Nakabeppu Y., Bedard P.J., Hope B.T., Nestler E.J., Jasmin B.J., Chen J.S., Iadarola M.J., St-Jean M., Wigle N., Blanchet P., Grondin R., Robertson G.S. Chronic alterations in dopaminergic neurotransmission produce a persistent elevation of deltaFosB-like protein(s) in both the rodent and primate striatum. Eur. J. Neurosci. 1996, 8(2):365-381.
85. D'souza U.M., Craig I.W. Functional polymorphisms in dopamine and serotonin pathway genes. Hum. Mutat. 2006, 27:1-13.
86. Dungo R., Deeks E.D. Istradefylline: first global approval. Drugs 2013, 73(8):875-882.
87. Dupre K.B., Eskow K.L., Negron G., Bishop C. The differential effects of 5-HT (1A) receptor stimulation on dopamine receptor-mediated abnormal involuntary movements and rotations in the primed hemiparkinsonian rat. Brain Res. 2007, 1158:135-143.
88. Dupre K.B., Eskow K.L., Steiniger A., Klioueva A., Negron G.E., Lormand L., Park J.Y., Bishop C. Effects of coincident 5-HT1A receptor stimulation and NMDA receptor antagonism on levodopa-induced dyskinesia and rotational behaviors in the hemi-parkinsonian rat. Psychopharmacology (Berl.) 2008, 199(1):99-108.
89. Durif F., Vidailhet M., Bonnet A.M., Blin J., Agid Y. Levodopa-induced dyskinesias are improved by fluoxetine. Neurology 1995, 45(10):1855-1858.
90. Durif F., Debilly B., Galitzky M., Morand D., Viallet F., Borg M., Thobois S., Broussolle E., Rascol O. Clozapine improves dyskinesias in Parkinson disease: a double-blind, placebo-controlled study. Neurology 2004, 62(3):381-388.
91. Echeverry-Alzate V., Tuda-Arízcun M., Bühler K.M., Santos Á., Giné E., Olmos P., Gorriti MÁ, Huertas E., Rodríguez de Fonseca F., López-Moreno J.A. Cocaine reverses the naltrexone-induced reduction in operant ethanol self-administration: the effects on immediate-early gene expression in the rat prefrontal cortex. Neuropharmacology 2012, 63(6):927-935.
92. Eggert K., Squillacote D., Barone P., Dodel R., Katzenschlager R., Emre M., Lees A.J., Rascol O., Poewe W., Tolosa E., Trenkwalder C., Onofrj M., Stocchi F., Nappi G., Kostic V., Potic J., Ruzicka E., Oertel W. German competence network on Parkinson's disease. Safety and efficacy of perampanel in advanced Parkinson's disease: a randomized, placebo-controlled study. Mov. Disord. 2010, 25(7):896-905.
93. Engeln M., Fasano S., Ahmed S.H., Cador M., Baekelandt V., Bezard E., Fernagut P.O. Levodopa gains psychostimulant-like properties after nigral dopaminergic loss. Ann. Neurol. 2013, 74(1):140-144.
94. Engeln M., Ahmed S.H., Vouillac C., Tison F., Bezard E., Fernagut P.O. Reinforcing properties of Pramipexole in normal and parkinsonian rats. Neurobiol. Dis. 2013, 49:79-86.
95. Erk S., Spitzer M., Wunderlich A.P., Galley L., Walter H. Cultural objects modulate reward circuitry. Neuroreport 2002, 13(18):2499-2503.
96. Eskow K.L., Gupta V., Alam S., Park J.Y., Bishop C. The partial 5-HT(1A) agonist buspirone reduces the expression and development of l-DOPA-induced dyskinesia in rats and improves l-DOPA efficacy. Pharmacol. Biochem. Behav. 2007, 87(3):306-314.
97. Eskow K.L., Dupre K.B., Barnum C.J., Dickinson S.O., Park J.Y., Bishop C. The role of the dorsal raphe nucleus in the development, expression, and treatment of L-dopa-induced dyskinesia in hemiparkinsonian rats. Synapse 2009, 63(7):610-620.
98. Evans A.H., Pavese N., Lawrence A.D., Tai Y.F., Appel S., Doder M., Brooks D.J., Lees A.J., Piccini P. Compulsive drug use linked to sensitized ventral striatal dopamine transmission. Ann. Neurol. 2006, 59(5):852-858.
99. Filip M., Zaniewska M., Frankowska M., Wydra K., Fuxe K. The importance of the adenosine A(2A) receptor-dopamine D(2) receptor interaction in drug addiction. Curr. Med. Chem. 2012, 19(3):317-355.
100. Fabbrini G., Brotchie J., Grandas F., Nomoto M., Goetz C.G. Levodopa-induced dyskinesias. Mov. Disord. 2007, 22(10):1379-1389.
101. Fasano A., Ricciardi L., Pettorruso M., Bentivoglio A.R. Management of punding in Parkinson's disease: an open-label prospective study. J. Neurol. 2011, 258(4):656-660.
102. Fiorentini C., Busi C., Gorruso E., Gotti C., Spano P., Missale C. Reciprocal regulation of dopamine D1 and D3 receptor function and trafficking by heterodimerization. Mol. Pharmacol. 2008, 74(1):59-69.
103. Fiorentini C., Busi C., Spano P., Missale C. Dimerization of dopamine D1 and D3 receptors in the regulation of striatal function. Curr. Opin. Pharmacol. 2010, 10(1):87-92.
104. Fishburn C.S., Carmon S., Fuchs S. Molecular cloning and characterisation of the gene encoding the murine D4 dopamine receptor. FEBS Lett. 1995, 361(2-3):215-219.
105. Forget B., Wertheim C., Mascia P., Pushparaj A., Goldberg S.R., Le Foll B. Noradrenergic alpha1 receptors as a novel target for the treatment of nicotine addiction. Neuropsychopharmacology 2010, 35(8):1751-1760.
106. Fox S.H., Henry B., Hill M.P., Peggs D., Crossman A.R., Brotchie J.M. Neural mechanisms underlying peakdose dyskinesia induced by levodopa and apomorphine are distinct: evidence from the effects of the alpha(2) adrenoceptor antagonist idazoxan. Mov. Disord. 2001, 16:642-650.
107. Fox S., Silverdale M., Kellett M., Davies R., Steiger M., Fletcher N., Crossman A., Brotchie J. Non-subtype-selective opioid receptor antagonism in treatment of levodopa-induced motor complications in Parkinson's disease. Mov. Disord. 2004, 19(5):554-560.
108. Fox S.H., Lang A.E., Brotchie J.M. Translation of nondopaminergic treatments for levodopa-induced dyskinesia from MPTP-lesioned nonhuman primates to phase IIa clinical studies: keys to success and roads to failure. Mov. Disord. 2006, 21(10):1578-1594.
109. Foltynie T., Cheeran B., Williams-Gray C.H., Edwards M.J., Schneider S.A., Weinberger D., Rothwell J.C., Barker R.A., Bhatia K.P. BDNF val66met influences time to onset of levodopa induced dyskinesia in Parkinson's disease. J. Neurol. Neurosurg. Psychiatry 2009, 80:141-144.
110. Frosini D., Pesaresi I., Cosottini M., Belmonte G., Rossi C., Dell'Osso L., Murri L., Bonuccelli U., Ceravolo R., et al. Parkinson's disease and pathological gambling: results from a functional MRI study. Mov. Disord. 2010, 25(14):2449-2453.
111. Fuxe K., Agnati L.F., Jacobsen K., Hillion J., Canals M., Torvinen M., Tinner-Staines B., Staines W., Rosin D., Terasmaa A., Popoli P., Leo G., Vergoni V., Lluis C., Ciruela F., Franco R., Ferré S. Receptor heteromerization in adenosine A2A receptor signaling: relevance for striatal function and Parkinson's disease. Neurology 2003, 61(11 Suppl. 6):S19-S23.
112. Garcia-Ruiz P.J., Martinez Castrillo J.C., Alonso-Canovas A., Herranz Barcenas A., Vela L., Sanchez Alonso P., Mata M., Olmedilla Gonzalez N., Mahillo Fernandez I. Impulse control disorder in patients with Parkinson's disease under dopamine agonist therapy: a multicentre study. J. Neurol. Neurosurg. Psychiatry 2014, 85(8):840-844.
113. Gardin J.M., Schumacher D., Constantine G., Davis K.D., Leung C., Reid C.L. Valvular abnormalities and cardiovascular status following exposure to dexfenfluramine or phentermine/fenfluramine. JAMA 2000, 283(13):1703-1709.
114. Gardoni F., Picconi B., Ghiglieri V., Polli F., Bagetta V., Bernardi G., Cattabeni F., Di Luca M., Calabresi P. A critical interaction between NR2B and MAGUK in l-DOPA induced dyskinesia. J. Neurosci. 2006, 26(11):2914-2922.
115. Gardoni F., Sgobio C., Pendolino V., Calabresi P., Di Luca M., Picconi B. Targeting NR2A-containing NMDA receptors reduces Levodopa-induced dyskinesias. Neurobiol. Aging 2012, 33(9):2138-2144.
116. Gasparini F., Lingenhöhl K., Stoehr N., Flor P.J., Heinrich M., Vranesic I., Biollaz M., Allgeier H., Heckendorn R., Urwyler S., Varney M.A., Johnson E.C., Hess S.D., Rao S.P., Sacaan A.I., Santori E.M., Veliçelebi G., Kuhn R. 2-Methyl-6-(phenylethynyl)-pyridine (MPEP), a potent, selective and systemically active mGlu5 receptor antagonist. Neuropharmacology 1999, 38(10):1493-1503.
117. Gasparini F., Bilbe G., Gomez-Mancilla B., Spooren W. mGluR5 antagonists: discovery, characterization and drug development. Curr. Opin. Drug Discov. Dev. 2008, 11(5):655-665.
118. Gerlach M., Halley P., Riederer P., van den Buuse M. The effect of piribedil on levodopa-induced dyskinesias in a rat model of Parkinson's disease: differential role of a2 adrenergic mechanisms. J. Neural Transm. 2013, 120(1):31-36.
119. Gilpin N.W., Koob G.F. Effects of β-adrenoceptor antagonists on alcohol drinking by alcohol-dependent rats. Psychopharmacology (Berl.) 2010, 212(3):431-439.
120. Ginsburg B.C., Pinkston J.W., Lamb R.J. The potency of fluvoxamine to reduce ethanol self-administration decreases with concurrent availability of food. Behav. Pharmacol. 2012, 23(2):134-142.
121. Goeldner C., Lutz P.E., Darcq E., Halter T., Clesse D., Ouagazzal A.M., Kieffer B.L. Impaired emotional-like behavior and serotonergic function during protracted abstinence from chronic morphine. Biol. Psychiatry 2011, 69(3):236-244.
122. Goetz C.G., Damier P., Hicking C., et al. Sarizotan as a treatment for dyskinesias in Parkinson's disease: a double-blind placebo-controlled trial. Mov. Disord. 2007, 22:179-186.
123. Goetz C.G., Laska E., Hicking C., Damier P., Müller T., Nutt J., Warren Olanow C., Rascol O., Russ H. Placebo influences on dyskinesia in Parkinson's disease. Mov. Disord. 2008, 23:700-707.
124. Gold S.J., Hoang C.V., Potts B.W., Porras G., Pioli E., Kim K.W., Nadjar A., Qin C., LaHoste G.J., Li Q., Bioulac B.H., Waugh J.L., Gurevich E., Neve R.L., Bezard E. RGS9-2 negatively modulates L-3,4-dihydroxyphenylalanine-induced dyskinesia in experimental Parkinson's disease. J. Neurosci. 2007, 27(52):14338-14348.
125. Gomez-Mancilla B., Bedard P.J. Effect of D1 and D2 agonists and antagonists on dyskinesia produced by l-dopa in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated monkeys. J. Pharmacol. Exp. Ther. 1991, 259(1):409-413.
126. Gomez-Mancilla B., Bedard P.J. Effect of nondopaminergic drugs on levodopa induced dyskinesias in MPTP-treated monkeys. Clin. Neuropharmacol. 1993, 16:418-427.
127. Graham W.C., Sambrook M.A., Crossman A.R. Differential effect of chronic dopaminergic treatment on dopamine D1 and D2 receptors in the monkey brain in MPTP-induced parkinsonism. Brain Res. 1993, 602(2):290-303.
128. Grandas F., Galiano M.L., Tabernero C. Risk factors for levodopa-induced dyskinesias in Parkinson's disease. J. Neurol. 1999, 246(12):1127-1133.
129. Grant J.E., Potenza M.N., Hollander E., Cunningham-Williams R., Nurminen T., Smits G., Kallio A. Multicenter investigation of the opioid antagonist nalmefene in the treatment of pathological gambling. Am. J. Psychiatry 2006, 163(2):303-312.
130. Grant J.E., Kim S.W., Hartman B.K. A double-blind, placebo-controlled study of the opiate antagonist naltrexone in the treatment of pathological gambling urges. J. Clin. Psychiatry 2008, 69(5):783-789.
131. Grégoire L., Samadi P., Graham J., Bédard P., Bartoszyk G., Di Paolo T. Low doses of sarizotan reduce dyskinesias and maintain antiparkinsonian efficacy of Levodopa in parkinsonian monkeys. Parkinsonism Relat. Disord. 2009, 15(6):445-452.
132. Grondin R., Hadj Tahar A., Doan V.D., Ladure P., Bédard P.J. Noradrenoceptor antagonism with idazoxan improves Levodopa-induced dyskinesias in MPTP monkeys. Naunyn Schmiedebergs Arch. Pharmacol. 2000, 361(2):181-186.
133. Guigoni C., Li Q., Aubert I., Dovero S., Bioulac B.H., Bloch B., Crossman A.R., Gross C.E., Bezard E. Involvement of sensorimotor, limbic, and associative basal ganglia domains in l-3,4-dihydroxyphenylalanine-induced dyskinesia. J. Neurosci. 2005, 25(8):2102-2107.
134. Guigoni C., Doudnikoff E., Li Q., Bloch B., Bezard E. Altered D(1) dopamine receptor trafficking in parkinsonian and dyskinetic non-human primates. Neurobiol. Dis. 2007, 26(2):452-463.
135. Guigoni C., Bezard E. Involvement of canonical and non-canonical D1 dopamine receptor signalling pathways in L-dopa-induced dyskinesia. Parkinsonism Relat. Disord. 2009, 15(Suppl. 3):S64-S67.
136. Haber S.N. The place of dopamine in the cortico-basal ganglia circuit. Neuroscience 2014, 282C:248-257.
137. Hallett P.J., Standaert D.G. Rationale for and use of NMDA receptor antagonists in Parkinson's disease. Pharmacol. Ther. 2004, 102:155-174.
138. Hallett P.J., Dunah A.W., Ravenscroft P., Zhou S., Bezard E., Crossman A.R., Brotchie J.M., Standaert D.G. Alterations of striatal NMDA receptor subunits associated with the development of dyskinesia in the MPTP-lesioned primate model of Parkinson's disease. Neuropharmacology 2005, 48(4):503-516.
139. Haber S.N. The primate basal ganglia: parallel and integrative networks. J. Chem. Neuroanat. 2003, 26(4):317-330.
140. Hauser R.A., Schwarzschild M.A. Adenosine A2A receptor antagonists for Parkinson's disease rationale, therapeutic potential and clinical experience. Drugs Aging 2005, 22(6):471-482.
141. Hauser R.A., Shulman L.M., Trugman J.M., Roberts J.W., Mori A., Ballerini R., Sussman N.M. Study of istradefylline in patients with Parkinson's disease on levodopa with motor fluctuations. Mov. Disord. 2008, 23(15):2177-2185. Istradefylline 6002-US-013 Study Group.
142. Hauser R.A., Cantillon M., Pourcher E., Micheli F., Mok V., Onofrj M., Huyck S., Wolski K. Preladenant in patients with Parkinson's disease and motor fluctuations: a phase 2, double-blind, randomised trial. Lancet Neurol. 2011, 10(3):221-229.
143. Hayes D.J., Greenshaw A.J. 5-HT receptors and reward-related behaviour: a review. Neurosci. Biobehav. Rev. 2011, 35(6):1419-1449.
144. Häggkvist J., Lindholm S., Franck J. The opioid receptor antagonist naltrexone attenuates reinstatement of amphetamine drug-seeking in the rat. Behav. Brain Res. 2009, 197(1):219-224.
145. Henry B., Fox S.H., Crossman A.R., Brotchie J.M. Mu- and delta-opioid receptor antagonists reduce levodopa-induced dyskinesia in the MPTP-lesioned primate model of Parkinson's disease. Exp. Neurol. 2001, 171(1):139-146.
146. Henry B., Duty S., Fox S.H., Crossman A.R., Brotchie J.M. Increased striatal pre-proenkephalin B expression is associated with dyskinesia in Parkinson's disease. Exp. Neurol. 2003, 183(2):458-468.
147. Herrero M.T., Levy R., Ruberg M., Luquin M.R., Villares J., Guillen J., Faucheux B., Javoy-Agid F., Guridi J., Agid Y., Obeso J.A., Hirsch E.C. Consequence of nigrostriatal denervation and Levodopa therapy on the expression of glutamic acid decarboxylase messenger RNA in the pallidum. Neurology 1996, 47(1):219-224.
148. Hershey T., Black K.J., Stambuk M.K., Carl J.L., McGee-Minnich L.A., Perlmutter J.S. Altered thalamic response to levodopa in Parkinson's patients with dopa-induced dyskinesias. Proc. Natl. Acad. Sci. U.S.A. 1998, 95(20):12016-12021.
149. Hicks C.W., Pandya M.M., Itin I., Fernandez H.H. Valproate for the treatment of medication-induced impulse-control disorders in three patients with Parkinson's disease. Parkinsonism Relat. Disord. 2011, 17:379-381.
150. Hill M.P., Girard F., Keywood C., et al. ADX48621, a novel mGlu5 negative allosteric modulator alleviates levodopa-induced chorea and dystonia in the MPTP lesioned macaque model of Parkinson's disease. Mov. Disord. 2010, 25(Suppl. 2):S281.
151. Hillion J., Canals M., Torvinen M., Casado V., Scott R., Terasmaa A., Hansson A., Watson S., Olah M.E., Mallol J., Canela E.I., Zoli M., Agnati L.F., Ibanez C.F., Lluis C., Franco R., Ferre S., Fuxe K. Coaggregation, cointernalization, and codesensitization of adenosine A2A receptors and dopamine D2 receptors. J. Biol. Chem. 2002, 277(20):18091-18097.
152. Hirano S., Asanuma K., Ma Y., Tang C., Feigin A., Dhawan V., Carbon M., Eidelberg D. Dissociation of metabolic and neurovascular responses to levodopa in the treatment of Parkinson's disease. J. Neurosci. 2008, 28(16):4201-4209.
153. Hodge C.W., Miles M.F., Sharko A.C., Stevenson R.A., Hillmann J.R., Lepoutre V., Besheer J., Schroeder J.P. The mGluR5 antagonist MPEP selectively inhibits the onset and maintenance of ethanol self-administration in C57BL/6J mice. Psychopharmacology (Berl.) 2006, 183(4):429-438.
154. Holden C. 'Behavioral' addictions: do they exist?. Science 2001, 294(5544):980-982.
155. Homberg J.R. Serotonin and decision making processes. Neurosci Biobehav Rev. 2012, 36(1):218-236.
156. Horikawa S., Takai T., Toyosato M., Takahashi H., Noda M., Kakidani H., Kubo T., Hirose T., Inayama S., Hayashida H., et al. Isolation and structural organization of the human preproenkephalin B gene. Nature 1983, 306(5943):611-614.
157. Hou H., Wang C., Jia S., Hu S., Tian M. Brain dopaminergic system changes in drug addiction: a review of positron emission tomography findings. Neurosci. Bull. 2014, 30(5):765-776.
158. Huot P., Johnston T.H., Koprich J.B., Aman A., Fox S.H., Brotchie J.M. L-745,870 reduces L-DOPA-induced dyskinesia in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-lesioned macaque model of Parkinson's disease. J. Pharmacol. Exp. Ther. 2012, 342(2):576-585.
159. Huot P., Johnston T.H., Koprich J.B., Winkelmolen L., Fox S.H., Brotchie J.M. Regulation of cortical and striatal 5-HT1A receptors in the MPTP-lesioned macaque. Neurobiol. Aging 2012, 33(1):207.e9-207.e19.
160. Huot P., Johnston T.H., Koprich J.B., Fox S.H., Brotchie J.M. The pharmacology of levodopa-induced dyskinesia in Parkinson's disease. Pharmacol. Rev. 2013, 65(1):171-222.
161. Ibáñez A., Blanco C., Perez de Castro I., Fernandez-Piqueras J., Sáiz-Ruiz J. Genetics of pathological gambling. J. Gambl. Stud. 2003, 19(1):11-22.
162. Iravani M.M., Jackson M.J., Kuoppamäki M., Smith L.A., Jenner P. 3,4-Methylenedioxymethamphetamine (ecstasy) inhibits dyskinesia expression and normalizes motor activity in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated primates. J. Neurosci. 2003, 23(27):9107-9115.
163. Jenner P. Treatment of the later stages of Parkinson's disease - pharmacological approaches now and in the future. Transl. Neurodegener. 2015, 4:3.
164. Jiménez-Jiménez F.J., Alonso-Navarro H., García-Martín E., Agúndez J.A. COMT gene and risk for Parkinson's disease: a systematic review and meta-analysis. Pharmacogenet. Genomics 2014, 24(7):331-339.
165. Johansen-Berg H., Behrens T.E., Robson M.D., Drobnjak I., Rushworth M.F., Brady J.M., Smith S.M., Higham D.J., Matthews P.M. Changes in connectivity profiles define functionally distinct regions in human medial frontal cortex. Proc. Natl. Acad. Sci. U.S.A. 2004, 101(36):13335-13340.
166. Johansson P.A., Andersson M., Andersson K.E., Cenci M.A. Alterations in cortical and basal ganglia levels of opioid receptor binding in a rat model of l-DOPA-induced dyskinesia. Neurobiol. Dis. 2001, 8(2):220-239.
167. Johnston T.H., Fox S.H., Piggott M.J., Savola J.M., Brotchie J.M. The a2 adrenergic antagonist fipamezole improves quality of levodopa action in parkinsonian primates. Mov. Disord. 2010, 25(13):2084-2093.
168. Joutsa J., Martikainen K., Vahlberg T., Kaasinen V. Effects of dopamine agonist dose and gender on the prognosis of impulse control disorders in Parkinson's disease. Parkinsonism Relat. Disord. 2012, 18(10):1079-1083.
169. Joutsa J., Martikainen K., Niemelä S., Johansson J., Forsback S., Rinne J.O., Kaasinen V. Increased medial orbitofrontal [18F]fluorodopa uptake in Parkinsonian impulse control disorders. Mov. Disord. 2012, 27(6):778-782.
170. June H.L., Cummings R., Eiler W.J., Foster K.L., McKay P.F., Seyoum R., Garcia M., McCane S., Grey C., Hawkins S.E., Mason D. Central opioid receptors differentially regulate the nalmefene-induced suppression of ethanol- and saccharin-reinforced behaviors in alcohol-preferring (P) rats. Neuropsychopharmacology 2004, 29(2):285-299.
171. Kanda T., Jackson M.J., Smith L.A., Pearce R.K., Nakamura J., Kase H., Kuwana Y., Jenner P. Combined use of the adenosine A2A antagonist KW-6002 with or with selective D1 or D2 dopamine agonists increases antiparkinsonian activity but not dyskinesia in MPTP-treated monkeys. Exp. Neurol. 2000, 162:321-327.
172. Kaneko T., Minami M., Satoh M., Mizuno N. Immunocytochemical localization of mu-opioid receptor in the rat caudate-putamen. Neurosci. Lett. 1995, 184(3):149-152.
173. Kannari K., Yamato H., Shen H., Tomiyama M., Suda T., Matsunaga M. Activation of 5-HT(1A) but not 5-HT(1B) receptors attenuates an increase in extracellular dopamine derived from exogenously administered levodopa in the striatum with nigrostriatal denervation. J. Neuro-chem. 2001, 76:1346-1353.
174. Kannari K., Kurahashi K., Tomiyama M., Maeda T., Arai A., Baba M., Suda T., Matsunaga M. Tandospirone citrate, a selective 5-HT1A agonist, alleviates l-DOPA-induced dyskinesia in patients with Parkinson's disease. No To Shinkei 2002, 54(2):133-137.
175. Kaiser R., Hofer A., Grapengiesser A., Gasser T., Kupsch A., Roots I., Brockmöller J. Levodopa-induced adverse effects in PD and dopamine transporter gene polymorphism. Neurology 2003, 60(11):1750-1755.
176. Katzenschlager R., Manson A.J., Evans A., Watt H., Lees A.J. Low dose quetiapine for drug induced dyskinesias in Parkinson's disease: a double blind cross over study. J. Neurol. Neurosurg. Psychiatry 2004, 75(2):295-297.
177. Kehagia A.A., Housden C.R., Regenthal R., Barker R.A., Müller U., Rowe J., Sahakian B.J., Robbins T.W. Targeting impulsivity in Parkinson's disease using atomoxetine. Brain 2014, 137(Pt 7):1986-1997.
178. Kenny P.J., Paterson N.E., Boutrel B., Semenova S., Harrison A.A., Gasparini F., Koob G.F., Skoubis P.D., Markou A. Metabotropic glutamate 5 receptor antagonist MPEP decreased nicotine and cocaine self-administration but not nicotine and cocaine-induced facilitation of brain reward function in rats. Ann. N. Y. Acad. Sci. 2003, 1003:415-418.
179. King A., Cao D., Zhang L., Rueger S.Y. Effects of the opioid receptor antagonist naltrexone on smoking and related behaviors in smokers preparing to quit: a randomized controlled trial. Addiction 2013, 108(10):1836-1844.
180. Kirby L.G., Zeeb F.D., Winstanley C.A. Contributions of serotonin in addiction vulnerability. Neuropharmacology 2011, 61(3):421-432.
181. Kleim J.A., Chan S., Pringle E., et al. BDNF val66met polymorphism is associated with modified experience-dependent plasticity in human motor cortex. Nat. Neurosci. 2006, 9:735-737.
182. Klintenberg R., Svenningsson P., Gunne L., Andrén P.E. Naloxone reduces levodopa-induced dyskinesias and apomorphine-induced rotations in primate models of parkinsonism. J. Neural Transm. 2002, 109(10):1295-1307.
183. Knutson B., Adams C.M., Fong G.W., Hommer D. Anticipation of increasing monetary reward selectively recruits nucleus accumbens. J. Neurosci. 2001, 21(16):RC159.
184. Kobilka B.K. Structural insights into adrenergic receptor function and pharmacology. Trends Pharmacol. Sci. 2011, 32:213-218.
185. Kobylecki C., Cenci M.A., Crossman A.R., Ravenscroft P. Calcium-permeable AMPA receptors are involved in the induction and expression of l-DOPA-induced dyskinesia in Parkinson's disease. J. Neurochem. 2010, 114:499-511.
186. Kobylecki C., Hill M.P., Crossman A.R., Ravenscroft P. Synergistic antidyskinetic effects of topiramate and amantadine in animal models of Parkinson's disease. Mov. Disord. 2011, 26(13):2354-2363.
187. Koepp M.J., Gunn R.N., Lawrence A.D., Cunningham V.J., Dagher A., Jones T., Brooks D.J., Bench C.J., Grasby P.M. Evidence for striatal dopamine release during a video game. Nature 1998, 393(6682):266-268.
188. Konitsiotis S., Blanchet P.J., Verhagen L., Lamers E., Chase T.N. AMPA receptor blockade improves levodopa-induced dyskinesia in MPTP monkeys. Neurology 2000, 54:1589-1595.
189. Koran L.M., Chuong H.W., Bullock K.D., Smith S.C. Citalopram for compulsive shopping disorder: an open-label study followed by double-blind discontinuation. J. Clin. Psychiatry 2003, 64(7):793-798.
190. Kuan W.L., Zhao J.W., Barker R.A. The role of anxiety in the development of levodopa-induced dyskinesias in an animal model of Parkinson's disease, and the effect of chronic treatment with the selective serotonin reuptake inhibitor citalopram. Psychopharmacology (Berl.) 2008, 197(2):279-293.
191. Kurlan R. Disabling repetitive behaviors in Parkinson's disease. Mov. Disord. 2004, 19:433-437.
192. Lader M. Effectiveness of benzodiazepines: do they work or not?. Expert Rev. Neurother. 2006, 8:1189-1191.
193. Larson E.R., Ariano M.A. D3 and D2 dopamine receptors: visualization of cellular expression patterns in motor and limbic structures. Synapse 1995, 20(4):325-337.
194. Le Foll B., Gallo A., Le Strat Y., Lu L., Gorwood P. Genetics of dopamine receptors and drug addiction: a comprehensive review. Behav. Pharmacol. 2009, 20(1):1-17.
195. Lee J.Y., Lee E.K., Park S.S., Lim J.Y., Kim H.J., Kim J.S., Jeon B.S. Association of DRD3 and GRIN2B with impulse control and related behaviors in Parkinson's disease. Mov. Disord. 2009, 24(12):1803-1810.
196. Lee J.Y., Cho J., Lee E.K., Park S.S., Jeon B.S. Differential genetic susceptibility in diphasic and peak-dose dyskinesias in Parkinson's disease. Mov. Disord. 2011, 26(1):73-79.
197. Lee J.Y., Jeon B.S., Kim H.J., Park S.S. Genetic variant of HTR2A associates with risk of impulse control and repetitive behaviors in Parkinson's disease. Parkinsonism Relat. Disord. 2012, 18(1):76-78.
198. Leeman R.F., Potenza M.N. Similarities and differences between pathological gambling and substance use disorders: a focus on impulsivity and compulsivity. Psychopharmacology (Berl.) 2012, 219(2):469-490.
199. Lees A., Fahn S., Eggert K.M., Jankovic J., Lang A., Micheli F., Mouradian M.M., Oertel W.H., Olanow C.W., Poewe W., Rascol O., Tolosa E., Squillacote D., Kumar D. Perampanel, an AMPA antagonist, found to have no benefit in reducing "off" time in Parkinson's disease. Mov. Disord. 2012, 27(2):284-288.
200. Leey J., Setters B., Murphy P., Antimisiaris D., Miles T. Quetiapine-induced dystonia and agitation in Parkinson's disease with dementia: a case report. J. Am. Geriatr. Soc. 2009, 57(5):918-919.
201. Letchworth S.R., Sexton T., Childers S.R., Vrana K.E., Vaughan R.A., Davies H.M., Porrino L.J. Regulation of rat dopamine transporter mRNA and protein by chronic cocaine administration. J. Neurochem. 1999, 73(5):1982-1989.
202. Letchworth S.R., Nader M.A., Smith H.R., Friedman D.P., Porrino L.J. Progression of changes in dopamine transporter binding site density as a result of cocaine self-administration in rhesus monkeys. J. Neurosci. 2001, 21(8):2799-2807.
203. Lewitt P.A., Hauser R.A., Lu M., Nicholas A.P., Weiner W., Coppard N., Leinonen M., Savola J.M. Randomized clinical trial of fipamezole for dyskinesia in Parkinson disease (FJORD study). Neurology 2012, 79(2):163-169.
204. Lindgren H.S., Andersson D.R., Lagerkvist S., Nissbrandt H., Cenci M.A. l-DOPA-induced dopamine efflux in the striatum and the substantia nigra in a rat model of Parkinson's disease: temporal and quantitative relationship to the expression of dyskinesia. J. Neurochem. 2010, 112(6):1465-1476.
205. Lominac K.D., Kapasova Z., Hannun R.A., Patterson C., Middaugh L.D., Szumlinski K.K. Behavioral and neurochemical interactions between group I mGluR antagonists and ethanol: potential insight into their anti-addictive properties. Drug Alcohol Depend. 2006, 85:142-156.
206. Lu C.L., Ku Y.C., Lo S.M., Peng C.H., Tung C.S., Lin Y.W., Liu Y.P. Acute and subchronic effects of buspirone on attention and impulsivity in the five-choice serial reaction time task in rats. Neurosci. Lett. 2013, 556:210-215.
207. Lundblad M., Andersson M., Winkler C., Kirik D., Wierup N., Cenci M.A. Pharmacological validation of behavioural measures of akinesia and dyskinesia in a rat model of Parkinson's disease. Eur. J. Neurosci. 2002, 15(1):120-132.
208. Lull M.E., Freeman W.M., Vrana K.E., Mash D.C. Correlating human and animal studies of cocaine abuse and gene expression. Ann. N. Y. Acad. Sci. 2008, 1141:58-75.
209. Luquin M.R., Laguna J., Obeso J.A. Selective D2 receptor stimulation induces dyskinesia in parkinsonian monkeys. Ann. Neurol. 1992, 31(5):551-554.
210. Lyons K.E., Hubbie J.P., Troster A.I., Pahwa R., Koller W.C. Gender differences in Parkinson's disease. Clin. Neuropharmacol. 1998, 21:118-121.
211. Marazziti D., Corsi M., Baroni S., Consoli G., Catena-Dell'Osso M. Latest advancements in the pharmacological treatment of binge eating disorder. Eur. Rev. Med. Pharmacol. Sci. 2012, 16(15):2102-2107.
212. Manson A.J., Iakovidou E., Lees A.J. Idazoxan is ineffective for levodopa-induced dyskinesias in Parkinson's disease. Mov. Disord. 2000, 15(2):336-337.
213. Manson A.J., Katzenschlager R., Hobart J., Lees A.J. High dose naltrexone for dyskinesias induced by levodopa. J. Neurol. Neurosurg. Psychiatry. 2001, 70(4):554-556.
214. Marin C., Aguilar E., Rodríguez-Oroz M.C., Bartoszyk G.D., Obeso J.A. Local administration of sarizotan into the subthalamic nucleus attenuates levodopa-induced dyskinesias in 6-OHDA-lesioned rats. Psychopharmacology (Berl.) 2009, 204(2):241-250.
215. Marin C., Bonastre M., Mengod G., Cortés R., Giralt A., Obeso J.A., Schapira A.H. Early l-dopa, but not pramipexole, restores basal ganglia activity in partially 6-OHDA-lesioned rats. Neurobiol. Dis. 2014, 64:36-47.
216. Martin-Fardon R., Baptista M.A., Dayas C.V., Weiss F. Dissociation of the effects of MTEP [3-[(2-methyl-1,3-thiazol-4-yl)ethynyl]piperidine] on conditioned reinstatement and reinforcement: comparison between cocaine and a conventional reinforcer. J. Pharmacol. Exp. Ther. 2009, 329(3):1084-1090.
217. Mash D.C., Staley J.K. D3 dopamine and kappa opioid receptor alterations in human brain of cocaine-overdose victims. Ann. N. Y. Acad. Sci. 1999, 877:507-522.
218. Mash D.C., Pablo J., Ouyang Q., Hearn W.L., Izenwasser S. Dopamine transport function is elevated in cocaine users. J. Neurochem. 2002, 81(2):292-300.
219. Matsumoto M., Hidaka K., Tada S., Tasaki Y., Yamaguchi T. Low levels of mRNA for dopamine D4 receptor in human cerebral cortex and striatum. J. Neurochem. 1996, 66(3):915-919.
220. McElroy S.L., Hudson J.I., Malhotra S., Welge J.A., Nelson E.B., Keck P.E. Topiramate in the treatment of binge eating disorder associated with obesity: a randomized, placebo-controlled trial. Am. J. Psychiatry 2003, 160(2):255-261.
221. McElroy S.L., Kotwal R., Guerdjikova A.I., Welge J.A., Nelson E.B., Lake K.A., D'Alessio D.A., Keck P.E., Hudson J.I. Zonisamide in the treatment of binge eating disorder with obesity: a randomized controlled trial. J. Clin. Psychiatry 2006, 67(12):1897-1906.
222. McElroy S.L., Guerdjikova A.I., Mori N., O'Melia A.M. Pharmacological management of binge eating disorder: current and emerging treatment options. Ther. Clin. Risk Manag. 2012, 8:219-241.
223. McRae A.L., Sonne S.C., Brady K.T., Durkalski V., Palesch Y. A randomized, placebo-controlled trial of buspirone for the treatment of anxiety in opioid-dependent individuals. Am. J. Addict. 2004, 13(1):53-63.
224. McRae A.L., Brady K.T., Carter R.E. Buspirone for treatment of marijuana dependence: a pilot study. Am. J. Addict. 2006, 15(5):404.
225. Meador-Woodruff J.H., Little K.Y., Damask S.P., Mansour A., Watson S.J. Effects of cocaine on dopamine receptor gene expression: a study in the postmortem human brain. Biol. Psychiatry 1993, 34(6):348-355.
226. Mehta A.K., Ticku M.K. An update on GABAA receptors. Brain Res. Brain Res. Rev. 1999, 29:196-217.
227. Meng F., Xie G.X., Thompson R.C., Mansour A., Goldstein A., Watson S.J., Akil H. Cloning and pharmacological characterization of a rat kappa opioid receptor. Proc. Natl. Acad. Sci. U.S.A. 1993, 90(21):9954-9958.
228. Merello M., Nouzeilles M.I., Cammarota A., Leiguarda R. Effect of memantine (NMDA antagonist) on Parkinson's disease: a double-blind crossover randomized study. Clin. Neuropharmacol. 1999, 22(5):273-276.
229. Mestre T.A., Strafella A.P., Thomsen T., Voon V., Miyasaki J. Diagnosis and treatment of impulse control disorders in patients with movement disorders. Ther. Adv. Neurol Disord. 2013, 6(3):175-188.
230. Milstein J.A., Dalley J.W., Robbins T.W. Methylphenidate-induced impulsivity: pharmacological antagonism by beta-adrenoreceptor blockade. J. Psychopharmacol. 2010, 24(3):309-321.
231. Minami M., Satoh M. Molecular biology of the opioid receptors: structures, functions and distributions. Neurosci. Res. 1995, 23(2):121-145.
232. Missale C., Nash S.R., Robinson S.W., Jaber M., Caron M.G. Dopamine receptors: from structure to function. Physiol. Rev. 1998, 78(1):189-225.
233. Moeller F.G., Dougherty D.M., Barratt E.S., Schmitz J.M., Swann A.C., Grabowski J. The impact of impulsivity on cocaine use and retention in treatment. J. Subst. Abuse Treat. 2001, 21(4):193-198.
234. Molina J.A., Sáinz-Artiga M.J., Fraile A., Jiménez-Jiménez F.J., Villanueva C., Ortí-Pareja M., Bermejo F. Pathologic gambling in Parkinson's disease: a behavioral manifestation of pharmacologic treatment?. Mov. Disord. 2000, 15(5):869-872.
235. Montastruc J.L., Rascol O., Senard J.M. Glutamate antagonists and Parkinson's disease: a review of clinical data. Neurosci. Biobehav. Rev. 1997, 21:477-480.
236. Morgenstern J., Kuerbis A.N., Chen A.C., Kahler C.W., Bux D.A., Kranzler H.R.A. randomized clinical trial of naltrexone and behavioral therapy for problem drinking men who have sex with men. J. Consult Clin. Psychol. 2012, 80(5):863-875.
237. Morin N., Morissette M., Grégoire L., Gomez-Mancilla B., Gasparini F., Di Paolo T. Chronic treatment with MPEP, an mGlu5 receptor antagonist, normalizes basal ganglia glutamate neurotransmission in Levodopa-treated parkinsonian monkeys. Neuropharmacology 2013, 73:216-231.
238. Murata M., Hasegawa K., Kanazawa I. Zonisamide improves motor function in Parkinson's disease: a randomized, double-blind study. Neurology 2007, 68:45-50. Japan Zonisamide on PD Study Group.
239. Napier T.C., Corvol J.C., Grace A.A., Roitman J.D., Rowe J., Voon V., Strafella A.P. Linking neuroscience with modern concepts of impulse control disorders in Parkinson's disease. Mov. Disord. 2015, 30(2):141-149.
240. Naranjo C.A., Knoke D.M. The role of selective serotonin reuptake inhibitors in reducing alcohol consumption. J. Clin. Psychiatry 2001, 62(Suppl. 20):18-25.
241. Navailles S., Bioulac B., Gross C., De Deurwaerdère P. Chronic l-DOPA therapy alters central serotonergic function and l-DOPA-induced dopamine release in a region-dependent manner in a rat model of Parkinson's disease. Neurobiol. Dis. 2011, 41(2):585-590.
242. Nestler E.J. Review. Transcriptional mechanisms of addiction: role of DeltaFosB. Philos. Trans. R. Soc. Lond. B Biol. Sci. 2008, 363(1507):3245-3255.
243. Newman-Tancredi A., Kleven M.S. Comparative pharmacology of antipsychotics possessing combined dopamine D2 and serotonin 5-HT1A receptor properties. Psychopharmacology (Berl.) 2011, 216(4):451-473.
244. Nichols D.E., Nichols C.D. Serotonin receptors. Chem. Rev. 2008, 108(5):1614-1641.
245. Nicoletti F., Bockaert J., Collingridge G.L., Conn P.J., Ferraguti F., Schoepp D.D., Wroblewski J.T., Pin J.P. Metabotropic glutamate receptors: from the workbench to the bedside. Neuropharmacology 2011, 60(7-8):1017-1041.
246. Nieoullon A. Dopamine and the regulation of cognition and attention. Prog. Neurobiol. 2002, 67(1):53-83.
247. Nisbet A.P., Foster O.J., Kingsbury A., Eve D.J., Daniel S.E., Marsden C.D., Lees A.J. Preproenkephalin and preprotachykinin messenger RNA expression in normal human basal ganglia and in Parkinson's disease. Neuroscience 1995, 66(2):361-376.
248. Noda M., Furutani Y., Takahashi H., Toyosato M., Hirose T., Inayama S., Nakanishi S., Numa S. Cloning and sequence analysis of cDNA for bovine adrenal preproenkephalin. Nature 1982, 295(5846):202-206.
249. Nutt D.J., Lingford-Hughes A., Erritzoe D., Stokes P.R. The dopamine theory of addiction: 40 years of highs and lows. Nat. Rev. Neurosci. 2015, 16(5):305-312.
250. Obeso J.A., Marin C., Rodriguez-Oroz C., Blesa J., Benitez-Temiño B., Mena-Segovia J., Rodríguez M., Olanow C.W. The basal ganglia in Parkinson's disease: current concepts and unexplained observations. Ann. Neurol. 2008, 64 Suppl. 2:S30-S46.
251. Obeso J.A., Rodríguez-Oroz M.C., Benitez-Temino B., Blesa F.J., Guridi J., Marin C., Rodriguez M. Functional organization of the basal ganglia: therapeutic implications for Parkinson's disease. Mov. Disord. 2008, 23 Suppl. 3:S548-S559.
252. Obeso J.A., Rodriguez-Oroz M.C., Stamelou M., Bhatia K.P., Burn D.J. The expanding universe of disorders of the basal ganglia. Lancet 2014, 384(9942):523-531.
253. Oh J.D., Bibbiani F., Chase T.N. Quetiapine attenuates levodopa-induced motor complications in rodent and primate parkinsonian models. Exp. Neurol. 2002, 177(2):557-564.
254. Ohmura Y., Kumamoto H., Tsutsui-Kimura I., Minami M., Izumi T., Yoshida T., Yoshioka M. Tandospirone suppresses impulsive action by possible blockade of the 5-HT1A receptor. J. Pharmacol. Sci. 2013, 122(2):84-92.
255. Okai D., Samuel M., Askey-Jones S., David A.S., Brown R.G. Impulse control disorders and dopamine dysregulation in Parkinson's disease: a broader conceptual framework. Eur. J. Neurol. 2011, 18(12):1379-1383.
256. Olanow C.W., Damier P., Goetz C.G., Mueller T., Nutt J., Rascol O., Serbanescu A., Deckers F., Russ H. Multicenter, open-label, trial of sarizotan in Parkinson disease patients with levodopa-induced dyskinesias (the SPLENDID Study). Clin. Neuropharmacol. 2004, 27(2):58-62.
257. Olanow C.W., Obeso J.A., Stocchi F. Continuous dopamine-receptor treatment of Parkinson's disease: scientific rationale and clinical implications. Lancet Neurol. 2006, 5(8):677-687.
258. Oliveri R.L., Annesi G., Zappia M., Civitelli D., Montesanti R., Branca D., Nicoletti G., Spadafora P., Pasqua A.A., Cittadella R., Andreoli V., Gambardella A., Aguglia U., Quattrone A. Dopamine D2 receptor gene polymorphism and the risk of levodopa-induced dyskinesias in PD. Neurology 1999, 53(7):1425-1430.
259. Ory-Magne F., Corvol J.C., Azulay J.P., Bonnet A.M., Brefel-Courbon C., Damier P., Dellapina E., Destée A., Durif F., Galitzky M., Lebouvier T., Meissner W., Thalamas C., Tison F., Salis A., Sommet A., Viallet F., Vidailhet M., Rascol O. Withdrawing amantadine in dyskinetic patients with Parkinson disease: the AMANDYSK trial. Neurology 2014, 82(4):300-307. NS-Park CIC Network.
260. O'Sullivan S.S., Evans A.H., Lees A.J. Dopamine dysregulation syndrome. CNS Drugs 2009, 23(2):157-170.
261. O'Sullivan S.S., Wu K., Politis M., Lawrence A.D., Evans A.H., Bose S.K., Djamshidian A., Lees A.J., Piccini P. Cue-induced striatal dopamine release in Parkinson's disease-associated impulsive-compulsive behaviours. Brain 2011, 134(Pt 4):969-978.
262. Otis J.M., Mueller D. Inhibition of β-adrenergic receptors induces a persistent deficit in retrieval of a cocaine-associated memory providing protection against reinstatement. Neuropsychopharmacology 2011, 36(9):1912-1920.
263. Ouattara B1, Hoyer D., Grégoire L., Morissette M., Gasparini F., Gomez-Mancilla B., Di Paolo T. Changes of AMPA receptors in MPTP monkeys with levodopa-induced dyskinesias. Neuroscience 2010, 167(4):1160-1167.
264. Paille F., Martini H. Nalmefene: a new approach to the treatment of alcohol dependence. Subst. Abuse Rehabil. 2014, 5:87-94.
265. Papay K., Xie S.X., Stern M., Hurtig H., Siderowf A., Duda J.E., Minger J., Weintraub D. Naltrexone for impulse control disorders in Parkinson disease: a placebo-controlled study. Neurology 2014, 83(9):826-833.
266. Parent A., Hazrati L.N. Functional anatomy of the basal ganglia. I. The cortico-basal ganglia-thalamo-cortical loop. Brain Res. Rev. 1995, 20:91-127.
267. Evaluation of dyskinesias in a pilot, randomized, placebo-controlled trial of remacemide in advanced Parkinson disease. Arch. Neurol. 2001, 58(10):1660-1668. Parkinson Study Group.
268. Paterson N.E., Semenova S., Gasparini F., Markou A. The mGluR5 antagonist MPEP decreased nicotine self-administration in rats and mice. Psychopharmacology (Berl.) 2003, 167(3):257-264.
269. Paquette M.A., Anderson A.M., Lewis J.R., Meshul C.K., Johnson S.W., Paul Berger S. MK-801 inhibits levodopa-induced abnormal involuntary movements only at doses that worsen parkinsonism. Neuropharmacology 2010, 58(7):1002-1008.
270. Paquette M.A., Martinez A.A., Macheda T., Meshul C.K., Johnson S.W., Berger S.P., Giuffrida A. Anti-dyskinetic mechanisms of amantadine and dextromethorphan in the 6-OHDA rat model of Parkinson's disease: role of NMDA vs. 5-HT1A receptors. Eur. J. Neurosci. 2012, 36(9):3224-3234.
271. Pearce R.K., Banerji T., Jenner P., Marsden C.D. De novo administration of ropinirole and bromocriptine induces less dyskinesia than Levodopa in the MPTP-treated marmoset. Mov. Disord. 1998, 13(2):234-241.
272. Perez-Lloret S., Rey M.V., Fabre N., Ory F., Spampinato U., Brefel-Courbon C., Montastruc J.L., Rascol O. Prevalence and pharmacological factors associated with impulse-control disorder symptoms in patients with Parkinson disease. Clin. Neuropharmacol. 2012, 35(6):261-265.
273. Pérez-Otaño I., Ehlers M.D. Homeostatic plasticity and NMDA receptor trafficking. Trends Neurosci. 2005, 28(5):229-238.
274. Petrovic P., Pleger B., Seymour B., Klöppel S., De Martino B., Critchley H., Dolan R.J. Blocking central opiate function modulates hedonic impact and anterior cingulate response to rewards and losses. J. Neurosci. 2008, 28(42):10509-10516.
275. Pettorruso M., Martinotti G., Di Nicola M., Onofrj M., Di Giannantonio M., Conte G., Janiri L. Amantadine in the treatment of pathological gambling: a case report. Front. Psychiatry 2012, 3:102.
276. Picconi B., Centonze D., Håkansson K., Bernardi G., Greengard P., Fisone G., Cenci M.A., Calabresi P. Loss of bidirectional striatal synaptic plasticity in l-DOPA-induced dyskinesia. Nat. Neurosci. 2003, 6(5):501-506.
277. Picconi B., Ghiglieri V., Bagetta V., Barone I., Sgobio C., Calabresi P. Striatal synaptic changes in experimental parkinsonism: role of NMDA receptor trafficking in PSD. Parkinsonism Relat. Disord. 2008, 14(Suppl. 2):S145-S149.
278. Picconi B., Bagetta V., Ghiglieri V., Paillè V., Di Filippo M., Pendolino V., Tozzi A., Giampà C., Fusco F.R., Sgobio C., Calabresi P. Inhibition of phosphodiesterases rescues striatal long-term depression and reduces levodopa-induced dyskinesia. Brain 2011, 134(Pt 2):375-387.
279. Politis M., Loane C., Wu K., O'Sullivan S.S., Woodhead Z., Kiferle L., Lawrence A.D., Lees A.J., Piccini P. Neural response to visual sexual cues in dopamine treatment-linked hypersexuality in Parkinson's disease. Brain 2013, 136(Pt 2):400-411.
280. Pomierny-Chamioło L., Rup K., Pomierny B., Niedzielska E., Kalivas P.W., Filip M. Metabotropic glutamatergic receptors and their ligands in drug addiction. Pharmacol. Ther. 2014, 142(3):281-305.
281. Pondal M., Marras C., Miyasaki J., Moro E., Armstrong M.J., Strafella A.P., Shah B.B., Fox S., Prashanth L.K., Phielipp N., Lang A.E. Clinical features of dopamine agonist withdrawal syndrome in a movement disorders clinic. J. Neurol. Neurosurg. Psychiatry 2013, 84(2):130-135.
282. Potenza M.N. Review: the neurobiology of pathological gambling and drug addiction: an overview and new findings. Philos. Trans. R. Soc. Lond. B Biol. Sci. 2008, 363:3181-3189.
283. Pourcher E., Bonnet A.M., Kefalos J., Dubois B., Agid Y. Effects of etybenzatropine and diazepam on levodopa-induced diphasic dyskinesias in Parkinson's disease. Mov. Disord. 1989, 4:195-201.
284. Przepiorka A.M., Blachnio A., Miziak B., Czuczwar S.J. Clinical approaches to treatment of Internet addiction. Pharmacol. Rep. 2014, 66(2):187-191.
285. Rabinak C.A., Nirenberg M.J. Dopamine agonist withdrawal syndrome in Parkinson disease. Arch. Neurol. 2010, 67(1):58-63.
286. Raja M., Bentivoglio A.R. Impulsive and compulsive behaviours during dopamine replacement treatment in Parkinson's Disease and other disorders. Curr. Drug Saf. 2012, 7:63-75.
287. Ramlackhansingh A.F., Bose S.K., Ahmed I., Turkheimer F.E., Pavese N., Brooks D.J. Adenosine 2A receptor availability in dyskinetic and nondyskinetic patients with Parkinson disease. Neurology 2011, 76(21):1811-1816.
288. Rao H., Mamikonyan E., Detre J.A., Siderowf A.D., Stern M.B., Potenza M.N., Weintraub D. Decreased ventral striatal activity with impulse control disorders in Parkinson's disease. Mov. Disord. 2010, 25(11):1660-1669.
289. Rascol O., Fabre N., Blin O., Poulik J., Sabatini U., Senard J.M., Ané M., Montastruc J.L., Rascol A. Naltrexone, an opiate antagonist, fails to modify motor signs in patients with Parkinson's disease. Mov. Disord. 1994, 9(4.):437-440.
290. Rascol O., Sabatini U., Brefel C., Fabre N., Rai S., Senard J.M., Celsis P., Viallard G., Montastruc J.L., Chollet F. Cortical motor overactivation in parkinsonian patients with Levodopa-induced peak-dose dyskinesia. Brain 1998, 121(Pt 3):527-533.
291. Rascol O., Brooks D.J., Korczyn A.D., De Deyn P.P., Clarke C.E., Lang A.E. A five-year study of the incidence of dyskinesia in patients with early Parkinson's disease who were treated with ropinirole or levodopa. N. Engl. J. Med. 2000, 342:1484-2149.
292. Rascol O., Arnulf I., Peyro-Saint Paul H., Brefel-Courbon C., Vidailhet M., Thalamas C., Bonnet A.M., Descombes S., Bejjani B., Fabre N., Montastruc J.L., Agid Y. Idazoxan, an alpha-2 antagonist, and Levodopa-induced dyskinesias in patients with Parkinson's disease. Mov. Disord. 2001, 16(4):708-713.
293. Rascol O., Barone P., Behari M., Emre M., Giladi N., Olanow C.W., Ruzicka E., Bibbiani F., Squillacote D., Patten A., Tolosa E. Perampanel in Parkinson disease fluctuations: a double-blind randomized trial with placebo and entacapone. Clin. Neuropharmacol. 2012, 35(1):15-20.
294. Ray N.J., Miyasaki J.M., Zurowski M., Ko J.H., Cho S.S., Pellecchia G., Antonelli F., Houle S., Lang A.E., Strafella A.P. Extrastriatal dopaminergic abnormalities of DA homeostasis in Parkinson's patients with medication-induced pathological gambling: a [11C] FLB-457 and PET study. Neurobiol. Dis. 2012, 48(3):519-525.
295. Raymond N.C., Grant J.E., Coleman E. Augmentation with naltrexone to treat compulsive sexual behavior: a case series. Ann. Clin. Psychiatry 2010, 22(1):56-62.
296. Reichmann H. Long-term treatment with dopamine agonists in idiopathic Parkinson's disease. J. Neurol. 2000, 247(Suppl. 4). IV/17-9.
297. Reuter J., Raedler T., Rose M., Hand I., Gläscher J., Büchel C. Pathological gambling is linked to reduced activation of the mesolimbic reward system. Nat. Neurosci. 2005, 8(2):147-148.
298. Riahi G., Morissette M., Samadi P., Parent M., Di Paolo T. Basal ganglia serotonin 1B receptors in parkinsonian monkeys with l-DOPA-induced dyskinesia. Biochem. Pharmacol. 2013, 86(7):970-978.
299. Riddle J.L., Rokosik S.L., Napier T.C. Pramipexole- and methamphetamine-induced reward-mediated behavior in a rodent model of Parkinson's disease and controls. Behav. Brain Res. 2012, 233(1):15-23.
300. Rieck M., Schumacher-Schuh A., Altmann V., Francisconi C.L.M., Fagundes P.T.B., Monte P.L., Callegari-Jacwes S.M., Rieder C.R.M., Hutz M.H. DRD2 haplotype is associated with dyskinesia induced by levodopa therapy in Parkinson's disease patients. Pharmacogenomics 2012, 13(5):1701-1710.
301. Rioux L., Frohna P.A., Joyce J.N., Schneider J.S. The effects of chronic levodopa treatment on pre- and postsynaptic markers of dopaminergic function in striatum of parkinsonian monkeys. Mov. Disord. 1997, 12(2):148-158.
302. Rivera A., Cuéllar B., Girón F.J., Grandy D.K., de la Calle A., Moratalla R. Dopamine D4 receptors are heterogeneously distributed in the striosomes/matrix compartments of the striatum. J. Neurochem. 2002, 80(2):219-229.
303. Robelet S., Melon C., Guillet B., Salin P., Kerkerian-Le Goff L. Chronic L-DOPA treatment increases extracellular glutamate levels and GLT1 expression in the basal ganglia in a rat model of Parkinson's disease. Eur. J. Neurosci. 2004, 20(5):1255-1266.
304. Robinson E.S., Dalley J.W., Theobald D.E., Glennon J.C., Pezze M.A., Murphy E.R., Robbins T.W. Opposing roles for 5-HT2A and 5-HT2C receptors in the nucleus accumbens on inhibitory response control in the 5-choice serial reaction time task. Neuropsychopharmacology 2008, 33(10):2398-2406.
305. Rokosik S.L., Napier T.C. Intracranial self-stimulation as a positive reinforcer to study impulsivity in a probability discounting paradigm. J. Neurosci. Methods 2011, 198(2):260-269.
306. Rodriguez A.L., Grier M.D., Jones C.K., Herman E.J., Kane A.S., Smith R.L., Williams R., Zhou Y., Marlo J.E., Days E.L., Blatt T.N., Jadhav S., Menon U.N., Vinson P.N., Rook J.M., Stauffer S.R., Niswender C.M., Lindsley C.W., Weaver C.D., Conn P.J. Discovery of novel allosteric modulators of metabotropic glutamate receptor subtype 5 reveals chemical and functional diversity and in vivo activity in rat behavioral models of anxiolytic and antipsychotic activity. Mol. Pharmacol. 2010, 78(6):1105-1123.
307. Rodriguez-Oroz M.C., Jahanshahi M., Krack P., Litvan I., Macias R., Bezard E., Obeso J.A. Initial clinical manifestations of Parkinson's disease: features and pathophysiological mechanisms. Lancet Neurol. 2009, 8(12):1128-1139.
308. Rodriguez-Oroz M.C., López-Azcárate J., Garcia-Garcia D., Alegre M., Toledo J., Valencia M., Guridi J., Artieda J., Obeso J.A. Involvement of the subthalamic nucleus in impulse control disorders associated with Parkinson's disease. Brain 2011, 134(Pt 1):36-49.
309. Rose S., Jackson M.J., Smith L.A., Stockwell K., Johnson L., Carminati P., Jenner P. The novel adenosine A2a receptor antagonist ST1535 potentiates the effects of a threshold dose of l-DOPA in MPTP treated common marmosets. Eur. J. Pharmacol. 2006, 546(1-3):82-87.
310. Rose S., Ramsay Croft N., Jenner P. The novel adenosine A2a antagonist ST1535 potentiates the effects of a threshold dose of l-dopa in unilaterally 6-OHDA-lesioned rats. Brain Res. 2007, 1133(1):110-114.
311. Rosin D.L., Robeva A., Woodard R.L., Guyenet P.G., Linden J. Immunohistochemical localization of adenosine A2A receptors in the rat central nervous system. J. Comp. Neurol. 1998, 401(2):163-186.
312. Rotondo A., Bosco D., Plastino M., Cosoli A., Bosco F. Clozapine for medication-related pathological gambling in Parkinson disease. Mov. Disord. 2010, 25(12):1994-1995.
313. Ruzicka E., Roth J., Jech R., Busek P. Subhypnotic doses of Zolpidem oppose dopaminergic induced dyskinesia on Parkinson's disease. Mov. Disord. 2000, 15:734-735.
314. Rylander D., Recchia A., Mela F., Dekundy A., Danysz W., Cenci M.A. Pharmacological modulation of glutamate transmission in a rat model of levodopa-induced dyskinesia: effects on motor behavior and striatal nuclear signaling. J. Pharmacol. Exp. Ther. 2009, 330(1):227-235.
315. Rylander D., Iderberg H., Li Q., et al. A mGluR5 antagonist under clinical development improves l-DOPA-induced dyskinesia in parkinsonian rats and monkeys. Neurobiol. Dis. 2010, 39:352-361.
316. Rylander D., Parent M., O'Sullivan S.S., Dovero S., Lees A.J., Erwan Bezard, Descarries L., Cenci M.A. Maladaptive plasticity of serotonin axon terminals in levodopa-induced dyskinesia. Ann. Neurol. 2010, 68(5):619-628.
317. Sage J.I., Hauser R.A., Cordon M.E., et al. Pilot study of the efficacy and safety of Piclozotan in Parkinson's disease patients with Levodopa induced motor complications. Mov. Disord. 2009, 24(Suppl. 1):S277.
318. Samadi P., Grégoire L., Bédard P.J. Opioid antagonists increase the dyskinetic response to dopaminergic agents in parkinsonian monkeys: interaction between dopamine and opioid systems. Neuropharmacology 2003, 45:954-963.
319. Samadi P., Grégoire L., Bédard P.J. The opioid agonist morphine decreases the dyskinetic response to dopaminergic agents in parkinsonian monkeys. Neurobiol. Dis. 2004, 16(1):246-253.
320. Samuel M., Rodriguez-Oroz M., Antonini A., Brotchie J.M., Ray Chaudhuri K., Brown R.G., Galpern W.R., Nirenberg M.J., Okun M.S., Lang A.E. Management of impulse control disorders in Parkinson's disease: controversies and future approaches. Mov. Disord. 2015, 30(2):150-159.
321. Savola J.M., Hill M., Engstrom M., Merivuori H., Wurster S., McGuire S.G., Fox S.H., Crossman A.R., Brotchie J.M. Fipamezole (JP-1730) is a potent alpha2 adrenergic receptor antagonist that reduces levodopa-induced dyskinesia in the MPTP-lesioned primate model of Parkinson's disease. Mov. Disord. 2003, 18(8):872-883.
322. Schrag A., Schott J.M. Epidemiological, clinical, and genetic characteristics of early-onset parkinsonism. Lancet Neurol. 2006, 5(4):355-363.
323. Schroeder J.P., Overstreet D.H., Hodge C.W. The mGluR5 antagonist MPEP decreases operant ethanol self-administration during maintenance and after repeated alcohol deprivations in alcohol-preferring (P) rats. Psychopharmacology 2005, 179:262-270.
324. Segal D.M., Moraes C.T., Mash D.C. Up-regulation of D3 dopamine receptor mRNA in the nucleus accumbens of human cocaine fatalities. Brain Res. Mol. Brain Res. 1997, 45(2):335-339.
325. Sharma J.C., Bachman C.G., Linazasoro G. Classifying risk factors for dyskinesia in Parkinson's disease. Park. Rel. Dis. 2010, 16:490-497.
326. Sharma A., Goyal V., Behari M., Srivastva A., Shukla G., Vibha D. Impulse control disorders and related behaviors (ICD-RBs) in Parkinson's disease patients: Assessment using "Questionnaire for impulsive-compulsive disorders in Parkinson's disease" (QUIP). Ann. Indian Acad. Neurol. 2015, 18(1):49-59.
327. Shelton K.L., Hendrick E.S., Beardsley P.M. Efficacy of buspirone for attenuating cocaine and methamphetamine reinstatement in rats. Drug Alcohol Depend. 2013, 129(3):210-216.
328. Silveira-Moriyama L., Evans A.H., Katzenschlager R., Lees A.J. Punding and dyskinesias. Mov. Disord. 2006, 21(12):2214-2217.
329. Silver M., Factor S.A. Valproic acid-induced parkinsonism: levodopa responsiveness with dyskinesia. Parkinsonism Relat. Disord. 2013, 19(8):758-760.
330. Silverdale M.A., Crossman A.R., Brotchie J.M. Striatal AMPA receptor binding is unaltered in the MPTP-lesioned macaque model of Parkinson's disease and dyskinesia. Exp. Neurol. 2002, 174(1):21-28.
331. Silverdale M.A., Nicholson S.L., Crossman A.R., Brotchie J.M. Topiramate reduces levodopa-induced dyskinesia in the MPTP-lesioned marmoset model of Parkinson's disease. Mov. Disord. 2005, 20:403-409.
332. Silverdale M.A., Kobylecki C., Hallett P.J., Li Q., Dunah A.W., Ravenscroft P., Bezard E., Brotchie J.M. Synaptic recruitment of AMPA glutamate receptor subunits in levodopa-induced dyskinesia in the MPTP-lesioned nonhuman primate. Synapse 2010, 64(2):177-180.
333. Smith L.A., Jackson M.J., Johnston L., Kuoppamaki M., Rose S., Al-Barghouthy G., Del Signore S., Jenner P. Switching from levodopa to the long-acting dopamine D2/D3 agonist piribedil reduces the expression of dyskinesia while maintaining effective motor activity in MPTP-treated primates. Clin. Neuropharmacol. 2006, 29(3):112-125.
334. Sriram A., Ward H.E., Hassan A., Iyer S., Foote K.D., Rodriguez R.L., McFarland N.R., Okun M.S. Valproate as a treatment for dopamine dysregulation syndrome (DDS) in Parkinson's disease. J. Neurol. 2013, 260(2):521-527.
335. Steeves T.D., Miyasaki J., Zurowski M., Lang A.E., Pellecchia G., Van Eimeren T., Rusjan P., Houle S., Strafella A.P. Increased striatal dopamine release in Parkinsonian patients with pathological gambling: a [11C]raclopride PET study. Brain 2009, 132(Pt 5):1376-1385.
336. Stiles G.L. Adenosine receptors. J. Biol. Chem. 1992, 267:6451-6454.
337. Stocchi F., Rascol O., Destee A., Hattori N., Hauser R.A., Lang A.E., Poewe W., Stacy M., Tolosa E., Gao H., Nagel J., Merschhemke M., Graf A., Kenney C., Trenkwalder C. AFQ056 in Parkinson patients with levodopa-induced dyskinesia: 13-week, randomized, dose-finding study. Mov. Disord. 2013, 28(13):1838-1846.
338. Suzuki T., Kobayashi K., Nagatsu T. Genomic structure and tissue distribution of the mouse dopamine D4 receptor. Neurosci. Lett. 1995, 199(1):69-72.
339. Svenningsson P., Hall H., Sedvall G., Fredholm B.B. Distribution of adenosine receptors in the postmortem human brain: an extended autoradiographic study. Synapse 1997, 27:322-335.
340. Thomas A., Bonanni L., Gambi F., Di Iorio A., Onofrj M. Pathological gambling in Parkinson disease is reduced by amantadine. Ann. Neurol. 2010, 68(3):400-404.
341. Tiihonen J., Krupitsky E., Verbitskaya E., Blokhina E., Mamontova O., Föhr J., Tuomola P., Kuoppasalmi K., Kiviniemi V., Zwartau E. Naltrexone implant for the treatment of polydrug dependence: a randomized controlled trial. Am. J. Psychiatry 2012, 169(5):531-536.
342. Tomiyama M., Kimura T., Maeda T., Kannari K., Matsunaga M., Baba M. A serotonin 5-HT1A receptor agonist prevents behavioral sensitization to L-DOPA in a rodent model of Parkinson's disease. Neurosci. Res. 2005, 52(2):185-194.
343. Traynelis S.F., Wollmuth L.P., McBain C.J., Menniti F.S., Vance K.M., Ogden K.K., Hansen K.B., Yuan H., Myers S.J., Dingledine R. Glutamate receptor ion channels: structure, regulation, and function. Pharmacol. Rev. 2010, 62(3):405-496.
344. Tremblay L., Worbe Y., Thobois S., Sgambato-Faure V., Féger J. Selective dysfunction of basal ganglia subterritories: from movement to behavioral disorders. Mov. Disord. 2015 Mar 15, [Epub ahead of print].
345. Ueda Y., Doi T., Tokumaru J., Willmore L.J. Effect of zonisamide on molecular regulation of glutamate and GABA transporter proteins during epileptogenesis in rats with hippocampal seizures. Brain. Res. Mol. Brain Res. 2003, 116(1-2):1-6.
346. Vandenbergh D.J., Rodriguez L.A., Miller I.T., Uhl G.R., Lachman H.M. High-activity catechol-O-methyltransferase allele is more prevalent in polysubstance abusers. Am. J. Med. Genet. 1997, 74(4):439-443.
347. van Huijstee A.N., Mansvelder H.D. Glutamatergic synaptic plasticity in the mesocorticolimbic system in addiction. Front. Cell Neurosci. 2015, 8:466.
348. Vallelunga A., Flaibani R., Formento-Dojot P., Biundo R., Facchini S., Antonini A. Role of genetic polymorphisms of the dopaminergic system in Parkinson's disease patients with impulse control disorders. Parkinsonism Relat. Disord. 2012, 18(4):397-399.
349. van de Velde K., Cras P., Helsen G. Acute chorea caused by valproate in an elderly. Acta Neurol Belg. 2011, 111(3):220-221.
350. Van Eimeren T., Pellecchia G., Cilia R., Ballanger B., Steeves T.D., Houle S., Miyasaki J.M., Zurowski M., Lang A.E., Strafella A.P. Drug-induced deactivation of inhibitory networks predicts pathological gambling in PD. Neurology 2010, 75(19):1711-1716.
351. Van Garpen J.A., Kumar N., Bower J.H., Wegland S., Ahlskog J.E. Levodopa associated dyskinesia risk among Parkinson disease patients in Olmstead County, Minnesota, 1976-1990. Arch. Neurol. 2006, 63:205-209.
352. Visanji N.P., Gomez-Ramirez J., Johnston T.H., Pires D., Voon V., Brotchie J.M., Fox S.H. Pharmacological characterization of psychosis-like behavior in the MPTP-lesioned nonhuman primate model of Parkinson's disease. Mov. Disord. 2006, 21(11):1879-1891.
353. Visanji N.P., Fox S.H., Johnston T., Reyes G., Millan M.J., Brotchie J.M. Dopamine D3 receptor stimulation underlies the development of levodopa-induced dyskinesia in animal models of Parkinson's disease. Neurobiol. Dis. 2009, 35(2):184-192.
354. Visanji N.P., Fox S.H., Johnston T.H., Millan M.J., Brotchie J.M. Alpha1-adrenoceptors mediate dihydroxyphenylalanine-induced activity in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-lesioned macaques. J. Pharmacol. Exp. Ther. 2009, 328(1):276-283.
355. Volkow N.D., Wang G.J., Fowler J.S., Gatley S.J., Logan J., Ding Y.S., Hitzemann R., Pappas N. Dopamine transporter occupancies in the human brain induced by therapeutic doses of oral methylphenidate. Am. J. Psychiatry 1998, 155(10):1325-1331.
356. Voon V., Fox S.H. Medication-related impulse control and repetitive behaviors in Parkinson disease. Arch. Neurol. 2007, 64(8):1089-1096.
357. Voon V., Mehta A.R., Hallet M. Impulse control disorders in Parkinson's disease: recent advances. Curr. Opin. Neurol. 2011, 24(4):324-330.
358. Voon V., Rizos A., Chakravartty R., Mulholland N., Robinson S., Howell N.A., Harrison N., Vivian G., Ray Chaudhuri K. Impulse control disorders in Parkinson's disease: decreased striatal dopamine transporter levels. J. Neurol Neurosurg. Psychiatry 2014, 85(2):148-152.
359. Vriend C., Nordbeck A.H., Booij J., van der Werf Y.D., Pattij T., Voorn P., Raijmakers P., Foncke E.M., van de Giessen E., Berendse H.W., van den Heuvel O.A. Reduced dopamine transporter binding predates impulse control disorders in Parkinson's disease. Mov. Disord. 2014, 29(7):904-911.
360. Wainberg M.L., Muench F., Morgenstern J., Hollander E., Irwin T.W., Parsons J.T., Allen A., O'Leary A. A double-blind study of citalopram versus placebo in the treatment of compulsive sexual behaviors in gay and bisexual men. J. Clin. Psychiatry 2006, 67(12):1968-1973.
361. Wang J., Liu Z.M.D., Chen B. Association study of dopamine D2, D3 receptor gene polymorphisms with motor fluctuations in PD. Neurology 2001, 56(12):1757-1759.
362. Wang J., Liu Z.L., Chen B. Dopamine D5 receptor gene polymorphism and the risk of levodopa-induced motor fluctuations in patients with Parkinson's disease. Neurosci. Lett. 2001, 308(1):21-24.
363. Watanabe M., Maemura K., Kanbara K., Tamayama T., Hayasaki H. GABA and GABA receptors in the central nervous system and other organs. Int. Rev. Cytol. 2002, 213:1-47.
364. Watanabe M., Harada S., Nakamura T., Ohkoshi N., Yoshizawa K., Hayashi A., Shoji S. Association between catechol-O-methyltransferase gene polymorphisms and wearing-off and dyskinesia in Parkinson's disease. Neuropsychobiology 2003, 48(4):190-193.
365. Weintraub D., Hoops S., Shea J.A., Lyons K.E., Pahwa R., Driver-Dunckley E.D., Adler C.H., Potenza M.N., Miyasaki J., Siderowf A.D., Duda J.E., Hurtig H.I., Colcher A., Horn S.S., Stern M.B., Voon V. Validation of the questionnaire for impulsive-compulsive disorders in Parkinson's disease. Mov. Disord. 2009, 24(10):1461-1467.
366. Weintraub D., Koester J., Potenza M.N., Siderowf A.D., Stacy M., VoonV, Whetteckey J., Wunderlich G.R., Lang A.E. Impulse control disorders in Parkinson disease: a cross-sectional study of 3090 patients. Arch. Neurol. 2010, 67(5):589-595.
367. Weintraub D., Sohr M., Potenza M.N., Siderowf A.D., Stacy M., Voon V., Whetteckey J., Wunderlich G.R., Lang A.E. Amantadine use associated with impulse control disorders in Parkinson disease in cross-sectional study. Ann. Neurol. 2010, 68(6):963-968.
368. Weintraub D., David A.S., Evans A.H., Grant J.E., Stacy M. Clinical spectrum of impulse control disorders in Parkinson's disease. Mov. Disord. 2015, 30(2):121-127.
369. Westin J.E., Vercammen L., Strome E.M., Konradi C., Cenci M.A. Spatiotemporal pattern of striatal ERK1/2 phosphorylation in a rat model of Levodopa-induced dyskinesia and the role of dopamine D1 receptors. Biol. Psychiatry 2007, 62:800-810.
370. Willuhn I., Wanat M.J., Clark J.J., Phillips P.E. Dopamine signaling in the nucleus accumbens of animals self-administering drugs of abuse. Curr. Top. Behav. Neurosci. 2010, 3:29-71.
371. Winhusen T., Brady K.T., Stitzer M., Woody G., Lindblad R., Kropp F., Brigham G., Liu D., Sparenborg S., Sharma G., VanVeldhuisen P., Adinoff B., Somoza E. Evaluation of buspirone for relapse-prevention in adults with cocaine dependence: an efficacy trial conducted in the real world. Contemp. Clin. Trials. 2012, 33(5):993-1002.
372. Wise R.A. Dopamine, learning and motivation. Nat. Rev. 2004, 5(6):483-494.
373. Wise R.A. Roles for nigrostriatal - not just mesocorticolimbic - dopamine in reward and addiction. Trends Neurosci. 2009, 32(10):517-524.
374. Wolters ECh, van der Werf Y.D., van den Heuvel O.A. Parkinson's disease-related disorders in the impulsive-compulsive spectrum. J. Neurol. 2008, 255(Suppl. 5):48-56.
375. Wu R.M., Chiu H.C., Wang M., Chen R.C. Risk factors on the occurrence of response fluctuations and dyskinesias in Parkinson's disease. J. Neural Transm. Park. Dis. Dement. Sect. 1993, 5(2):127-133.
376. Xia Y., Goebel D.J., Kapatos G., Bannon M.J. Quantitation of rat dopamine transporter mRNA: effects of cocaine treatment and withdrawal. J. Neurochem. 1992, 59(3):1179-1182.
377. Zalewska-Kaszubska J., Bajer B., Gorska D., Andrzejczak D., Dyr W., Bieńkowski P. Effect of repeated treatment with topiramate on voluntary alcohol intake and beta-endorphin plasma level in Warsaw alcohol high-preferring rats. Psychopharmacology (Berl.) 2013, 225(2):275-281.
378. Zappia M., Annesi G., Nicoletti G., Arabia G., Annesi F., Messina D., Pugliese P., Spadafora P., Tarantino P., Carrideo S., Civitelli D., De Marco E.V., Cirò-Candiano I.C., Gambardella A., Quattrone A. Sex Differences in clinical and genetic determinants of levodopa peak-dose dyskinesias in Parkinson disease: an exploratory study. Arch. Neurol. 2005, 62:601-605.
379. Zengin-Toktas Y., Authier N., Denizot H., Chassain C., Hafidi A., Llorca P.M., Durif F. Motivational properties of D2 and D3 dopamine receptors agonists and cocaine, but not with D1 dopamine receptors agonist and L-dopa, in bilateral 6-OHDA-lesioned rat. Neuropharmacology 2013, 70:74-82.
380. Zhang X., Andren P.E., Greengard P., Svenningsson P. Evidence for a role of the 5-HT1B receptor and its adaptor protein, p11, in levodopa treatment of an animal model of Parkinsonism. Proc. Natl. Acad. Sci. U.S.A. 2008, 105(6):2163-2168.